Instead, the goal of the validation cohort was to transform sufficient number of BCL from MS controls and PMS patients to disprove or validate differences in VEGF, TNF-α, and LT-α secretion among MS and controls and the relationship of these cytokines to the MS phenotype. This evidence concerns the gene VEGFA and myeloid sarcoma.